Retatrutide, developed by Soma Corp., is receiving significant attention as a novel therapy for obesity control . This dual-action drug combines the activity of a GLP-1 receptor stimulant and a GIP receptor activator , aiming to not only promote reduced body fat but also address underlying metabolic factors. Early patient studies have demonstrated